After Lixi: What Zealand Is Doing Next

Zealand CEO Britt Meelby Jensen says the Danish developer of novel peptides for treating gastrointestinal and metabolic diseases is successfully raising its global profile via a growing proprietary pipeline.

Magnify
Zealand's CEO Seeks To Focus Attention On Its Proprietary Pipeline • Source: Shutterstock

Denmark-basedZealand Pharma AS says its profile among international investors has benefited hugely since its shares were listed on the US Nasdaq last August, giving it exposure to highlight a promising late-stage proprietary pipeline and ongoing collaborations with Sanofi and Boehringer Ingelheim GMBH.

Hitherto largely known for developing the Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), the Danish biotech has under its CEO Britt...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.